Aspire Biopharma Holdings Inc. (Nasdaq: ASBP) provided a business update for the quarter ended September 30, 2025. During the third quarter, the company expanded its scientific team with the addition of Dr. Mark J. Jaroszeski, a tenured professor from the University of South Florida, to support development of its sublingual drug delivery technology. Aspire reported progress on its sublingual ED medication program, with plans to finalize formulation and manufacture a test product in the first half of 2026, and to begin a Phase 1 pharmacokinetic clinical cross-over study by mid-2026. The company highlighted the clinical validation of its technology with sublingual aspirin and noted a targeted New Drug Application (NDA) submission for this product in the first half of 2026. Aspire also pointed to continued commercial execution with Buzz Bomb Caffeine Company's second production order of two million servings of BUZZ BOMB™. In addition, Aspire filed an omnibus patent application with the U.S. Patent and Trademark Office to expand protection for its sublingual drug delivery system, supplementing its existing patents.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1112550) on December 04, 2025, and is solely responsible for the information contained therein.
Comments